Rew et al., 1991 - Google Patents
Proliferation characteristics of human colorectal carcinomas measured in vivoRew et al., 1991
- Document ID
- 6666929571986659982
- Author
- Rew D
- Wilson G
- Taylor I
- Weaver P
- Publication year
- Publication venue
- Journal of British Surgery
External Links
Snippet
The cell proliferation kinetics of 100 human colonic and rectal adenocarcinomas have been studied in vivo by bromodeoxyuridine infusion and multiparameter flow cytometry. A total of 97 patients, three with synchronous tumours, consented to receive a single bolus dose of …
- 230000035755 proliferation 0 title abstract description 21
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Rew et al. | Proliferation characteristics of human colorectal carcinomas measured in vivo | |
Witzig et al. | DNA ploidy and cell kinetic measurements as predictors of recurrence and survival in stages B2 and C colorectal adenocarcinoma | |
Cindolo et al. | Chromophobe renal cell carcinoma: comprehensive analysis of 104 cases from multicenter European database | |
Nordsmark et al. | The prognostic value of pimonidazole and tumour pO2 in human cervix carcinomas after radiation therapy: a prospective international multi-center study | |
Kubota et al. | Ki‐67‐determined growth fraction versus standard staging and grading parameters in colorectal carcinoma: a multivariate analysis | |
Kokal et al. | Tumor DNA content in resectable, primary colorectal carcinoma | |
Maier et al. | The clinical value of urinary cytology: 12 years of experience with 615 patients. | |
Ten Velde et al. | Flow cytometric analysis of DNA ploidy level in paraffin-embedded tissue of non-small-cell lung cancer | |
Kroll et al. | A comparison of cause-specific melanoma mortality and all-cause mortality in survival analyses after radiation treatment for uveal melanoma | |
Ohyama et al. | Proliferative activity and malignancy in human gastric cancers. Significance of the proliferation rate and its clinical application | |
Jaafari-Ashkavandi et al. | MCM3 and Ki67 proliferation markers in odontogenic cysts and ameloblastoma | |
Harlow et al. | Prognostic implications of proliferative activity and DNA aneuploidy in Astler-Coller Dukes stage C colonic adenocarcinomas | |
Schiepers et al. | The effect of preoperative radiation therapy on glucose utilization and cell kinetics in patients with primary rectal carcinoma | |
Enker et al. | DNA/RNA content and proliferative fractions of colorectal carcinomas: a five-year prospective study relating flow cytometry to survival | |
Taylor et al. | Flow cytometric DNA analysis of adrenocortical tumors in children | |
Bai et al. | Nomogram to predict incomplete cytoreduction for pseudomyxoma peritonei | |
Kaplan | Progress in thyroid cancer | |
Wang et al. | The use of platelet/lymphocyte ratio and cancer antigen 125 combined with magnetic resonance diffusion-weighted imaging in diagnosis of recurrent ovarian cancer and neuropathic pain | |
Heimann et al. | Significance of DNA content abnormalities in small rectal cancers | |
Martin et al. | DNA content as a prognostic index in gestational trophoblastic neoplasia | |
Lin et al. | Operative strategy for follicular thyroid cancer in risk groups stratified by pTNM staging | |
Hermansen et al. | Flow cytometry and cytology as response indicators to M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) | |
Petrelli et al. | The utility of squamous cell carcinoma antigen for the follow‐up of patients with squamous cell carcinoma of the anal canal | |
Ellis et al. | The content of tumor DNA as an indicator of prognosis in patients with T1N0M0 and T2N0M0 carcinoma of the breast | |
Rew | GD zyxwvutsrqponmlkjihg |